The immune-mediated destruction of hematopoietic stem cells is implicated in the pathophysiology of aplastic anemia (AA). Immunosuppressive therapy (IST) using antithymocyte globulin and cyclosporine is successful in this setting. Eltrombopag is active in patients with refractory AA, presumably by increasing the bone marrow progenitors. METHODS: This phase 2 trial initially was designed to evaluate standard IST in newly diagnosed patients with severe AA and later was amended to add eltrombopag to simultaneously address immune destruction and stem cell depletion. The primary outcome was the overall response rate (ORR) at 3 months and 6 months. RESULTS: A total of 38 patients were enrolled: 17 (45%) received IST alone and 21 (55%) received additional eltrombopag. The ORR was 74%. Patients receiving IST plus eltrombopag had a similar ORR (76% vs 71%; P = .72), complete remission rate (38% vs 29%; P = .73), and median time to response (84 days vs 57 days; P = .30) compared with those receiving IST alone. The 2-year overall survival rate in the IST group was 91% compared with 82% for those patients treated with IST plus eltrombopag (P = .82). No cumulative toxicities were noted after the addition of eltrombopag. CONCLUSIONS: The addition of eltrombopag to standard IST was well tolerated and resulted in similar responses. Cancer 2018;124:4192-4201.
INTRODUCTION
Acquired aplastic anemia (AA) is a potentially fatal bone marrow failure syndrome characterized by a paucity of hematopoietic stem cells (HSCs) and progenitor cells with varying degrees of cytopenia and fatty infiltration of the bone marrow space. 1 Underlying mechanisms include immune-mediated attack, telomere defects, 2 and inherent HSC compartment insufficiency. These events may occur individually or in concert, mostly involving effector T cells. 3, 4 Historical treatment has included the use of high-dose chemotherapy and allogeneic stem cell transplantation as well as lymphotoxic immunosuppressive therapy (IST). The combination of horse antithymocyte globulin (hATG) with cyclosporine A (CsA) produced response rates of 60 to 80% and improved overall survival (OS) compared with either agent alone and with rabbit ATG. 5 Subsequently, the addition of CsA to steroids and hATG resulted in a significantly higher overall response rate (ORR) at 3 months when compared with hATG with steroids alone (65% vs 39%), without a survival difference noted. 6, 7 These results may be hindered by early infectious mortality. 8 The upfront use of granulocyte colony-stimulating factors (G-CSFs) with IST decreased the early mortality rate to 8%, with an ORR of 82% and a complete response (CR) rate of 43%. 9 Approximately 30% of patients remain refractory to conventional IST. 5, 10 This refractoriness may demonstrate incomplete ablation of autoreactive T cells or a profound depletion of HSCs in the presence of ongoing immune attack. Therefore, agents that engage HSC receptors and augment the pool of progenitors might be particularly beneficial.
Thrombopoietin (TPO) regulates platelet production, maturation, and release through binding of c-mpl on megakaryocytes. 11 C-mpl is expressed on HSCs and progenitor cells 12 and the addition of recombinant TPO was found to amplify primitive HSCs in murine studies. 13 Eltrombopag (E-PAG) is an oral synthetic small-molecule, noncompetitive, TPO agonist 14 that initially was approved by the US Food and Drug Administration (FDA) for the treatment of chronic immune thrombocytopenic purpura. 15 Single-agent activity of E-PAG was demonstrated in at least 1 lineage in 40 to 45% of patients with AA that was refractory to IST, 16 leading to its approval by the FDA in this setting.
Cancer November 1, 2018 We herein report the results of a phase 2 trial evaluating the combination of hATG, CsA, steroids, and G-CSF with and without E-PAG in patients with newly diagnosed severe AA. E-PAG-based combination therapy may increase response rates and expedite cell count recovery while halting immune-mediated HSC depletion.
MATERIALS AND METHODS

Study Design
The current study was an open-label, prospective, phase 2 trial conducted at The University of Texas MD Anderson Cancer Center in Houston (ClinicalTrials.gov identifier NCT01624805). It originally was designed to evaluate the combination of hATG, methylprednisolone, CsA, and G-CSF in patients with severe AA. The first 17 patients received IST plus G-CSF alone. After the encouraging results and FDA approval of E-PAG in patients with refractory AA, the protocol was amended to add E-PAG to IST plus G-CSF. The study was not sponsored and all patients were prescribed commercial E-PAG; therefore, the availability and time of initiation compared with the regimen of IST plus G-CSF depended on financial approval of the medication. The study was approved by the institutional review board and was conducted in concordance with the Declaration of Helsinki. All patients provided written informed consent.
Eligibility Criteria
Patients of all ages with newly diagnosed severe AA were eligible. Severe AA was defined by bone marrow cellularity of <30% and at least 2 of the following: an absolute neutrophil count (ANC) <0.5×10 9 /L, a pretransfusion platelet count <20×10 9 /L, or a pretransfusion reticulocyte count <20×10 9 /L. Patients were treatment-naive or previously had been treated with growth factors (excluding E-PAG). Other inclusion criteria comprised adequate hepatic and renal functions and an Eastern Cooperative Oncology Group performance status of 2. Patients with any uncontrolled illness and those with documented hypersensitivity to any of the component medications were excluded.
Treatment Plan
Before hATG, all patients received a subcutaneous test dose to check for potential hypersensitivity. The following combination was given: hATG at a dose of 40 mg/kg per day intravenously for 4 days; methylprednisone at a dose of 1 mg/kg per day intravenously daily for 4 days (before each dose of hATG) followed by oral prednisone that was tapered off over 30 days; subcutaneous G-CSF starting on day 5 as needed to keep the ANC at 1.5×10 9 /L; and CsA at a dose of 5 mg/kg orally daily starting on day 6 to maintain serum trough concentrations at approximately 200 mg/dL. CsA was continued for at least 6 months unless frequent dose reductions or interruptions were required because of major toxicity. E-PAG was introduced at a dose of 50 mg orally daily with escalation by 25 to 50 mg every 2 weeks to reach a maximum of 150 mg daily in the absence of platelet response. If platelet counts reached 120×10 9 /L or toxicity was considered to be related to E-PAG, the drug was withheld until the count dropped to <100×10 9 /L or there was resolution of the event. Patients were restarted at a dose of 50 mg daily and the dose was escalated as noted. For responders not meeting the above criteria, E-PAG was continued indefinitely or discontinued at the discretion of the treating physician. Enrolled patients received prophylactic antimicrobials and were transfused with blood products as per institutional policy.
Clinical Evaluation
Pretreatment evaluation included a complete history and physical examination, complete blood count with differential, and serum chemistry; bone marrow aspiration and biopsy within 1 month of enrollment; quantification of CD4/CD8 T-cell subsets; serum immunoglobulin level; polymerase chain reaction testing of the bone marrow for T-cell receptor (TCR) beta and gamma rearrangements; and peripheral blood flow cytometry for paroxysmal nocturnal hemoglobinuria (PNH) antigens (CD55 and CD59). Cytogenetic and mutational analyses were performed as previously described (see Supporting Table 1 ). 17, 18 Patients were reassessed with complete blood counts with differential and serum chemistry once or twice weekly during the first month of treatment and then every 2 to 4 weeks for up to 6 months. The serum CsA level was measured every 2 to 4 weeks while patients were receiving the drug. A repeat bone marrow biopsy and/ or aspiration for morphology and cytogenetics was performed at 3 months and 6 months.
Response Criteria
The primary objective of the current study was to evaluate the efficacy of the combination of hATG, methylprednisolone, CsA, and G-CSF, including complete responses (CRs) and partial responses (PRs). Secondary objectives were the tolerability and toxicities of the combination, time to achieve a response, duration of response, and OS. CR was defined as a bone marrow sample demonstrating <5% myeloblasts with normal maturation of all cell lines and no dysplasia, a peripheral blood ANC ≥1×10 hemoglobin ≥10 g/dL, and a platelet count ≥100 × 10 9 /L. PR was defined as transfusion independence with an ANC ≥0.5 × 10 9 /L, hemoglobin ≥8 g/dL, and a platelet count ≥20 × 10 9 /L. Responses were assessed at 3 months after the initiation of therapy and monthly thereafter to document best response. The duration of response was measured from the time of achieving a CR or PR until disease recurrence or progression. OS was measured from the time of study enrollment until death from any cause or the date of last follow-up.
Statistical Analysis
On the basis of historical data, the anticipated response rate was 65%. OS and duration of response were analyzed using the Kaplan-Meier method. The time to response (TTR) was defined as the interval between the initiation of treatment and the date of response. Log-rank and chi-square tests were applied to calculate the differences between risk groups with a level of statistical significance of P < .05. The Bayesian sequential method of Thall et al was used to perform safety monitoring. 19 The grading and reporting of adverse events (AEs) used the Cancer Therapy Evaluation Program of the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). Independent prognostic factors for response were assessed using logistic regression models and Cox proportional hazard models. The effect of response on survival and disease progression was analyzed by modeling response as a time-varying covariate in the Cox model.
RESULTS
Patient Characteristics
A total of 38 patients were enrolled: the first 17 patients received IST plus G-CSF alone and the remaining 21 patients received IST, G-CSF, and E-PAG. In the cohort receiving IST, G-CSF, and E-PAG, 13 of 21 patients (62%) initiated E-PAG within the first week (because of insurance coverage issues), with a median time to initiation of 5 days (range, 0-70 days). Patients treated with IST, G-CSF, and E-PAG were found to have a lower pretreatment ANC (median, 0.34×10 9 /L vs 0.73×10 9 /L; P = .002) and reticulocyte count (median, 0.9×10 9 /L vs 1.5×10 9 /L; P = .028). Flow cytometry for PNH was performed in 36 patients (95%) and clones were numerically more prevalent in the group treated with IST, G-CSF, and E-PAG compared with patients receiving IST and G-CSF (76% vs 67%; P = .7). TCR gene rearrangement was detected in 10 of 17 patients (59%) treated with IST and G-CSF and 7 of 19 patients (37%) receiving IST, G-CSF, and E-PAG (P = .31). The median baseline bone marrow cellularity was similar in both groups (Table 1) .
Efficacy
All 38 patients were evaluable for response ( Table 2 ). The median follow-up was 21 months (range, 3-49 months). Among the 17 patients treated with IST and G-CSF alone, the ORR was 71%, with 5 patients (29%) achieving a CR and 7 patients (41%) achieving a PR. Among the 21 patients treated with IST, G-CSF, and E-PAG, 16 responded (76%), with 8 CRs (38%) and 8 PRs (38%). The difference in the response rate between the 2 cohorts was not found to be statistically significant for either ORR (P = .72) or CR (P = .73); patients receiving IST, G-CSF, and E-PAG had a nonstatistically significant longer median TTR (84 days vs 57 days; P = .30).
Nonresponders had a lower median ANC (0.110 9 /L vs 0.510 9 /L; P = .05) and were less likely than responders to have monoclonal TCR (67% vs 100%; P = .02) (see Supporting Table 2 ). Among nonresponders, males were slightly underrepresented (40%), although the difference in sex between the groups was statistically insignificant (54% vs 40%; P = .71). Of the 30 patients whose samples were evaluated for gene mutations, 17 (57%) had detectable somatic/variant mutations with 11 of these 17 patients (65%) having 1 mutation. The median number of mutations per patient was 1 (range, 1-6 mutations), and included ASXL1 (6 patients), IDH1 (5 patients), NOTCH1 (5 patients), and KIT (4 patients).
Survival Endpoints
The median OS was not reached in either cohort (hazard ratio, 0.78; 95% confidence interval [95% CI], 0.09-6.69 [P = .82]) (Fig. 1) . The estimated 2-year OS rate was 91% in the cohort treated with IST and G-CSF versus 82% in the cohort receiving IST, G-CSF, and E-PAG. In each cohort, achieving a clinical response (CR or PR) was found to be predictive of improved survival at 2 years (P = .002).
The median OS for responders was not reached, compared with an OS of 9 months for nonresponders (hazard ratio, 0.05; 95% CI, 0.001-0.15 [P<.001]) (Fig. 2) . The estimated 3-year OS rate was 47% for nonresponders compared with 95% for responders (P<.001). For patients who achieved a CR, the estimated 4-year OS rate was 100%, compared with 92% in patients with PRs and 47% in those with no response (P = .0016) (Fig. 3) . Although a higher baseline ANC and TCR monoclonality were associated with response (P = .05 vs P = .02, respectively), none of these factors and others
Cancer November 1, 2018 (including the presence of a PNH clone, reticulocyte count, and cytogenetics) was found to predict for improved response on multivariate analysis. When analyzing factors predictive of OS, including segregation by treatment cohort (IST and G-CSF vs IST, G-CSF, and E-PAG), PNH clone, cytogenetics, baseline white blood cell count, reticulocyte count, and clinical response, only achieving a CR or PR was found to be predictive of improved survival on multivariate analysis (P = .02).
The median recurrence-free survival was not reached in either group (Fig. 4) and remained statistically insignificant (95% CI, 0.015-1.432 [P = .10]). All responders from the IST and G-CSF treatment arm maintained their responses at 2 years compared with 76% in the patients treated with IST, G-CSF, and E-PAG. At a median follow-up of 15 months (range, 1-33 months), among the 28 responders in both cohorts, a total of 16 patients (57%) had continued some form of maintenance treatment: 10 (36%) were receiving CsA and E-PAG and 6 (21%) were receiving CsA alone, with stable counts noted. Among nonresponders (10 patients), the counts were maintained while receiving CsA in 2 patients (20%) and CsA and E-PAG in another 2 patients (20%). Indeed, 16 of the 28 responders from both cohorts (57%) continued to receive either CsA alone (21%) or CsA and E-PAG (36%), and had their counts maintained with no disease recurrences (Fig. 5) .
Five patients underwent allogeneic stem cell transplantation for refractoriness (1 from the cohort of patients receiving IST and G-CSF and 4 from the cohort receiving IST, G-CSF, and E-PAG).
At a median follow-up of 21 months (range, 3-49 months), cytogenetic abnormalities were detected in 5 patients (2 of those treated with IST and G-CSF and 3 of those treated with IST, G-CSF, and E-PAG): 3 involved partial deletion of chromosome 7, 1 involved deletion of chromosome Y, and 1 involved addition of chromosome Y. Cancer November 1, 2018 Cancer November 1, 2018
Safety and Tolerability
All patients were eligible for evaluation of toxicity (Table 3) . Overall, both treatment arms had acceptable toxicities. Seven patients from both cohorts (18%) experienced infusion reactions despite extensive premedication. The reactions mostly were of low grade (with the exception of a grade 3 event in the cohort receiving IST and G-CSF, for which the patient was taken off study) with no anaphylaxis events noted; these reactions included chills, dyspnea, fever, and rash, and were managed with increased doses of steroids, antihistamines, and meperidine as needed. In both treatment cohorts, infectious complications requiring hospital admission (grade ≥3) were infrequent, occurring in 5 of 38 patients (13%). These included 1 case of urinary tract infection and 1 case of cytomegalovirus viremia (both in the cohort treated with IST and G-CSF), as well as 2 cases of febrile neutropenia of undetermined source. The most common nonhematological AEs included hypertension (5 patients [29%] in the IST and G-CSF cohort), rash (11%; 4 patients in the IST and G-CSF cohort), nausea (11%), and nonspecific joint pain (11%; 4 patients). Seven patients (18%) reported fatigue, including 2 cases of grade 3 to 4 fatigue reported in the IST and G-CSF group. Two patients from the IST and G-CSF cohort had grade 3 to 4 transaminitis and hyperbilirubinemia that were reversible with drug adjustment. Other grade 3 events included subarachnoid hemorrhage (1 patient) and serum sickness (1 patient), both of which occurred in the IST and G-CSF cohort. A 70-year-old patient treated with 12  14  16  18  20  22  24  26  28  30  32  34  36  38  40  42  44  46  48  50  52  54  56  58 IST and G-CSF died of bacterial sepsis on day 63. Therefore, the 100-day mortality rate for the current study was 3%.
DISCUSSION
In patients with severe AA, responses to conventional IST have been stagnant at approximately 60% for 30 years. 20 The current study initially was designed to evaluate the combination of IST and G-CSF. After the encouraging results noted with the use of E-PAG in patients with refractory AA, we allowed the addition of E-PAG to the combination of IST and G-CSF and studied its tolerability and efficacy. The primary endpoint was the ORR because historical data correlated CR with improved survival and reduced clonal evolution (CE). The ORR of 71% obtained in the cohort treated with IST and G-CSF matches that of historical reports, whereas the 29% CR rate observed in the current study was higher than the historical rate of 10%. 21 When E-PAG was added concurrently to the combination of IST and G-CSF, the ORR increased from 71 to 76% and the CR rate from 29 to 38%, albeit these increases were statistically insignificant and with a longer median TTR. No specific baseline or laboratory markers were found to be predictive of better response.
Although patients in both groups were treated sequentially and not in a comparative randomized fashion, we nevertheless expected better responses with the addition of E-PAG to the combination of IST and G-CSF, but instead observed similar outcomes. This contrasts with the phase 2 trial by Townsley et al, 22 which enrolled 88 treatment-naive patients with severe AA to receive standard IST and E-PAG. In their study, E-PAG was administered at an upfront dose of 150 mg daily to 3 (24) 3 (18) 1 (6) 1 (5) 1 (5) 0 Peripheral neuropathy
Gingival hyperplasia Cancer November 1, 2018 cohorts: starting from day 14 until 6 months (cohort 1) or 3 months (cohort 2) or concurrently with hATG on day 1 and up to 6 months (cohort 3). The highest ORR and CR rate were recorded among those who received concurrent IST and E-PAG (92% and 54%, respectively, at 6 months). When comparing response rates from the current study with those reported in the study by Townsley et al, 22 we delineated some important differences. Patients treated on the current study were significantly older, with a median age of 60 years, compared with 32 years in the study by Townsley et al. Age is an important predictor of response to IST, 23 and likely had a major effect on the differences in overall outcomes. Second, selection bias, noncongruent baseline covariates, and differences in supportive care measures might represent confounding factors when current results are compared with historical controls and across studies. For example, all patients enrolled on the current study received G-CSF to shorten the duration of neutropenia and presumably mobilize hematopoietic progenitors to peripheral blood. 9 Although earlier studies using G-CSF in combination with IST 9 have reported a higher ORR (82%) compared with those without the use of G-CSF (65%), 6 other reports have failed to demonstrate any significantly better outcomes with the use of growth factors. 24 The latter finding has been attributed, in part, to the possible absence of G-CSF receptors on the surface of HSCs and progenitor cells. 24 E-PAG does not compete with TPO for c-MPL binding and therefore may activate hematopoiesis independently through JAK-STAT and MAPK pathways. 25 The lack of a significantly better ORR when E-PAG was used may be explained by the slower intrinsic impact on stem and progenitor cells (as reflected by the longer TTR, even in those patients who responded) compared with the faster effect on maturing megakaryocytes in patients with idiopathic thrombocytopenic purpura. 15 This also could reflect the possibility of profound and variably reversible HSC compartment depletion with heterogeneous repopulation capacities, even in the absence of an ongoing immune attack. Hence, using higher, earlier doses of E-PAG (as in the study by Townsley et al 22 or even >150 mg) may be necessary to generate a critical mass of HSCs capable of sustaining hematopoiesis. In the current study, only 13 of 21 patients (62%) were able to initiate E-PAG within the first week of IST (median, 5 days; range, 0-70 days) because of logistical delays (Fig. 4) , and the median dose per patient was 75 mg (range, 50-150 mg) during the 6-month study period. The cohort with the best response in the National Institutes of Health study started at a high dose (150 mg) on the first day of IST. The lack of uniformity in the timing of E-PAG initiation as well as the gradual dose escalation scheme applied from the previous study in patients with refractory AA, 26 coupled with a lower dose intensity, may have contributed to the lack of improved responses noted with the addition of E-PAG. Finally, we did not assess the impact of telomere length on responses in both groups in the current study, and therefore the effect of this variable cannot be excluded.
The majority of IST protocols have advised a 6-month course of CsA. Using this approach, hematologic disease recurrences were documented in 30 to 40% of patients >5 years after ATG therapy. 8 In the current study, we chronically continued lower doses of CsA after a slow taper from the initial protocol. 27 When feasible, we also continued E-PAG in an attempt to delay or prevent disease recurrences. Indeed, 16 of the 28 responders from both cohorts (57%) continued to receive CsA alone (21%) or CsA and E-PAG (36%) with no disease recurrences noted. However, longer follow-ups are needed, especially in patients continuing treatment with CsA and E-PAG.
At a median follow-up of 21 months (range, 3-49 months), 5 patients acquired cytogenetic abnormalities (2 in the IST and G-CSF cohort and 3 of the patients treated with IST, G-CSF, and E-PAG): 3 involving partial deletion of chromosome 7 (2 in the IST and G-CSF cohort with 1 evolving to Acute Myeloid Leukemia), 1 deletion of chromosome Y, and 1 addition of chromosome Y. Therefore, the estimated CE rate in the current study was 13%, and was 14% in patients receiving E-PAG. The risk of CE is variable, reportedly ranging from 1.7 to 57% over 5 to 11 years of follow-up, 6 ,28 with a common scenario of evolution to myelodysplastic syndrome with isolated monosomy 7.
28 Trisomy 8, del 13q, and del Y are far less common abnormalities. 28 Both CE and the acquisition of PNH clones may reflect mechanisms of immunologic escape. 8, 29 CE is of more theoretical concern in patients treated with E-PAG because 8 of the 43 patients with refractory AA (19%) studied by Olnes et al acquired cytogenetic lesions with dysplastic changes over a period of only a few months. 26 The follow-up for the current study remains relatively short (3-49 months), especially in patients continuing E-PAG beyond 6 months, and longer surveillance currently is being pursued.
Overall, both combinations were found to be safe in the current study, with expected and manageable AEs with no anaphylactic reactions or infusion-related deaths reported. A generally low rate of serious infections also
Cancer November 1, 2018 was noted, mostly including neutropenic fevers (overall 8%; grade 3 events in 3 patients) with a 100-day mortality rate of 3%. When compared with previous studies of hATG and CsA, 6, 9, 21, 30 this reduction in early infection-related mortality is clearly favorable and may be explained at least in part by the routine use of G-CSF and prophylactic antimicrobials at the study institution.
The results of the current study may reflect the real-life experience of patients with severe AA in whom the commercial supply of E-PAG may be limited by insurance authorization, pending regulatory approval of the medication in the frontline setting. The combination of IST, G-CSF, and E-PAG resulted in similar response rates compared with the combination of IST and G-CSF, and no cumulative toxicities were observed when E-PAG was added as adjunct therapy. Maximizing dose intensity and the earlier initiation of E-PAG may be important factors associated with higher responses. Longer follow-up also is needed to determine the effect of E-PAG, if any, on OS in patients with AA.
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